newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer